Dr. Daniel Spitz Co-Author of Expanded Phase 2 Study on Recurrent Platinum-Resistant Ovarian Cancer
- December 19, 2017
- News
West Palm Beach, FL – December 12, 2017…… Dr. Daniel Spitz, who practices at the Florida Cancer Specialists (FCS) location in West Palm Beach, was a co-author of a new study evaluating the safety and efficacy of Etirinotecan Pegol (EP) in women with recurrent platinum-resistant or refractory ovarian cancer (PROC).
According to the National Institutes of Health, the majority of patients with ovarian cancer experience disease recurrence and sometimes receive several lines of treatment. In clinical studies, a widely accepted classification defines ‘platinum refractory’ as disease progressing during therapy or within four weeks after the last dose; ‘platinum resistant’ is defined as disease progressing within six months of platinum-based therapy.
Published in the November 2017 issue of Gynecologic Oncology, the Phase 2 Study sought to demonstrate improved tolerability of EP, with a trend toward progression free survival (PFS) and the convenience of less frequent dosing administered in 21-day intervals.
The primary purpose of the study was to further define the activity of EP when it was administered as a fourth-line regimen in patients with PROC. The study demonstrated an overall response rate (ORR) of 15%, with clinical benefit achieved in over half of the patients and a median progression free survival (PFS) and overall survival (OS) of 4.4 months and 10.2 months, respectively. Compared to other single agents used in advanced PROC, these results were encouraging. The study concluded that “further evaluation earlier in the disease course and in combination is warranted.”
To read the full article: https://www.ncbi.nlm.nih.gov/pubmed/28935273
SOURCES:
Gynecologic Oncology 147 (2017) 276-2S2;
Therapeutic Advances in Medical Oncology, 2014 Sep; 6(5): 229–239.
